Since hyperinsulinemia is a key driver of tumor growth, agents like gliclazide that limit sustained insulin exposure may carry a lower oncogenic risk than those that promote persistent hyperinsulinemia [56,294]. This evidence concerns the gene INS and hyperinsulinism.